# Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00144859** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 82 (—)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive
- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** SB681323

## Key facts

- **NCT ID:** NCT00144859
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 82 (—)
- **Last updated:** 2012-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00144859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00144859, "Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00144859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*